Addressing Specific Hunger Patterns If a patient experiences intense head hunger or cravings that the GLP-1 is not fully suppressing, the stimulant effect of phentermine might be used to target those specific neurological triggers
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound) in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity
Therapeutic advantages and challenges of targeting central GLP-1 The potential therapeutic benefits of targeting the brains GLP-1 system are significant
GLP1 medications are FDA-approved for long-term weight management, and lipotropic injections are generally well tolerated
Storage and handling directly impact potency, which impacts results
Byun J-K, Park M, Lee S, Yun JW, Lee J, Kim JS, et al